Intodion
Empowering women to choose the number and timingofpregnancies iswidely recognized as a primary goal of reproductive rights advocates. It follows that such advocates should endorse women's full and direct access to contraception. Indeed, if this goal is central, then only compelling health concerns could justify restrictions such as a prescription requirement.
In the United States, historical circumstances and health concerns once restricted all decisions regarding access to contraceptives to physicians. Eighty percent of American women now use oral contraceptives during their lives,' yet these contraceptives have been provided onlyby prescription for the last 30 years. Because there is now considerable evidence for the safety of current low-dose oral contaceptives, we believe that it is time to rethink this practice. While we recognize the difficulty of balancing patient autonomy and clinical guidance, we conclude that safety and compliance concerns are no longer sufficient to justify maintaining the current level of clinical control over a woman's contraceptive selection. A national dialogue on this issue is overdue. Our goal is not to promote the use of oral contraceptives but to remove obstacles for women who decide to use this method. In contrast, we strongly support efforts to promote use of barrier methods among those at risk of sexually tansmitted diseases.
Histo,ica Cirnwtnces
The medicalized status of oral contraceptives derives in part from the history of family planning in this country. The influence of the 1873 Comstock Act, which made it a criminal offense to import, mail, or transport in interstate commerce any literature about birth control or any device designed to prevent conception or cause abortion, persisted for more than a century.2 Birth control advocate Margaret Sanger challenged this legislation but succeeded in circumventing it only by making physicians the key to contraceptive distribution. In 1936, the Supreme Court, in United States v One Package (the package being three diaphragms imported from Japan), allowed the "importation, sale, or carriage by mail of things which might intelligently be employed by conscientious and competentphysicians for the purpose of saving life or promoting the well-being of theirpatients" (emphasis added). Evidence that women can screen themselves accurately is provided by a Mexican study that compared 13 health indicators, primarily related to circulatory disease, among three groups ofcurrent users of oral contraceptives: women who had neverbeen examinedbya clinician for contraindications but who obtained oral contraceptives from a community-based distribution program (after completing a screening checklist) or directly from a pharmacy without prescription, and women who had been examined by a clinician for contraindications. Educational levels were low; only 19%o had advanced beyond elementary school. Yet health profiles ofwomen in the three groupswere similar. Women screened themselves for contraindications to oral contraceptives just as accurately as clinicians screened them. 5 General health screening. The broadest defense of prescription status is that it ensures regular health examinations, which in turn detect problems unrelated to the use of oral contraceptives. Underlying this defense is the opinion, usually unstated, that coercion based on the "carrot" ofa prescription for oral contraceptives is appropriate. We believe that it is not. Men face no comparable coercion. Should men be required to obtain an annual prescription for condoms to promote the early detection of testicular and prostate cancer? And regardless ofthe importance of routine exams to women, there are two additional, unexamined premises to consider. First, the "carrot" policy assumes that it would be worse for a woman's health to miss out on routine care than itwould be to miss out on taking oral contraceptives. Second, it assumes that policymakers, rather than women themselves, should make the decision.
Protection againstseually transmitted diseases. Viral sexually transmitted diseases cause much of the physical and emotional misery directy related to sexual intimacy in the United States, but concern that oral contraceptives do not protect against such diseases has no bearing on their prescription status. The concern regarding sexually transmitted diseases applies to all hormonal contraceptives, to periodic abstinence, to withdrawal, to intrauterine devices, to male and female sterilization, and-with respect to FHV Pubc Health Poliy Fonum infection-perhaps also to spermicides, the cervical cap, the sponge, and the diaphragm. 6 The appropriate public health response is education rather than restriction ofone or more contraceptive options. Those who are at risk of acquiring or transmitting sexually transmitted diseases need explicit education to help them recognize and reduce risk. For example, condoms and information on assessment of risk for sexually transmitted diseases could be packaged with all contraceptives sold, and recipients could be urged to use the condoms or give them to someone who might need them.
Swmnmay. In the case of many medications, need can be determined only by a skilled professional. The disease to be cured or managed must be diagnosed, and an appropriate therapy must be selected and sometimes professionally administered. In contrast, a woman herself determines her need for oral contraceptives; she assesses her own risk of pregnancy and sexually transmitted diseases and the costs and benefits of both pregnancy and alternative contraceptives. Professional services are not required for correct administration, overdose is not life threatening, and oral contraceptives are not addictive. Even selection of an appropriate initial product and dose does not require professional experise.
The vast majority of oral contraceptives now prescnbed are low-dose products containing either 30 ,g or 35 ,g ofthe synthetic estrogen ethinyl estradiol.7 Although the 30 products in this group contain seven different progestins, all provide similar biologic activity. Thus '14) , (3) interrupting use for one or more cycles (because the user perceives no need to obtain or cannot obtain resupply or because she mistakenly believes she needs to give her body a rest'5), (4) 
Others respond that such a decision would hardly be cost-effective. Some fear that manufacturers might discontinue deep price discounts to family planning clinics and, thus, that poor women who now obtain pills inexpensively might have to pay higher prices.
Others reason that manufacturers would have even more incentive to create brand loyalty. While the allocation of costs for oral contraceptives would likely shift if they were available without prescription, the overall social cost of their use would almost certainly decline. Administrative costs associated with prescriptions and the costs associated with visiting a clinician to obtain oral contraceptives would disappear altogether.
A final and serious concem is that over-the-counter status for oral contraceptives could threaten the survival of familplingclinics. Millions ofwomen using oral contraceptives receive primary health care from publicor nonprofit family planning clinics such as those operated by Planned Parenthood.2728 Particularly for young or poor women, such contact with clinics may be the chief portal into the health care system. These clinics provide countless services in addition to dispensing oral contraceptives: they educate and counsel patients about a range of health issues; refer women for specialized health care; screen for and treat sexually transmitted diseases; offer FHV testing; screen for breast cancer, cervical cancer, diabetes, and anemia; and treat gynecological problems. Women will continue to need these services regardless of the prescription status of oral contraceptives. Since financial support for family planning clinics is substantially based on reimbursement associated with contraceptive distnrbution-especially the distribution of oral contraceptives-a change in the regulatory status oforal contraceptives could threaten the economic viability of clinics. We will need to think carefully about the best ways of preserving the essential services for women that only clinics can now provide; the private health care system could not currently accommodate the enormous numbers ofwomen now served by clinics. The resolution ofthis important issue, however, hinges more on changing the reimbursement system to support and compensate clinics fully for the primary health services they provide than it does on the prescription status of oral contraceptives. As national health care reform proposals develop, the reimbursement system for family planning clinics will undoubtedly be altered regardless of any changes in rules regarding the distribution of oral contraceptives.
Creaing New Opfions
There are several alternatives to providing oral contraceptives by prescription (with the current package design and labeling) and selling them over the counter. Possibilities, many of which could be adopted simultaneously, range from minor changes that remove some obstacles to major policy shifts that substantially increase availability. Options that allow pharmacies to sell oral contraceptives over the counter could also require that blood pressure screening be available on site.
New Packaging Options
Several packaging options are available. For example, all oral contraceptives could be packaged in an identical 28- 
